Peregrine Pharmaceuticals, Inc. presented two groundbreaking preclinical studies at the 97th Annual Meeting of the American Association for Cancer Research (AACR) demonstrating that a mouse equivalent to its first-in-class anti-phospholipid (PS) agent Tarvacin™ (bavituximab) significantly increases survival in cisplatin-resistant breast cancer and radiotherapy-resistant brain cancer when given as part of a combination regimen.
In these studies, Tarvacin™ in combination with cisplatin or radiation was significantly more effective in increasing survival time than either agent alone.
Both studies also confirmed that Tarvacin's unique phospholipid target is up-regulated after cisplatin or radiation therapy, thereby contributing to the demonstrated efficacy of the combination regimens.
These preclinical studies were conducted by researchers at the University of Texas Southwestern Medical Center at
Read Peregrine’s complete press release.
Comment Preview